Want to see SE:SPEC full AI Analyst Report?
SPEC Stock Chart & Stats
kr0.18
kr0.10(5.82%)
At close: 4:00 PM EST
kr0.18
kr0.10(5.82%)
Day’s Range― - ―
52-Week Rangekr0.03 - kr0.24
Previous CloseN/A
Volume60.95K
Average Volume (3M)1.15M
Market Cap
kr56.83M
Enterprise Valuekr31.16
Total Cash (Recent Filing)kr16.59M
Total Debt (Recent Filing)kr2.19M
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding1,711,808,500
10 Day Avg. Volume1,242,664
30 Day Avg. Volume1,152,681
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.68
Price to Sales (P/S)0.00
P/FCF Ratio-1.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage On Balance SheetVery low debt-to-equity (~0.03) gives the company durable financial flexibility versus peers. This reduces near-term solvency risk, lowers fixed financing costs, and preserves optionality for funding clinical development or commercialization steps over the next 2–6 months without immediate debt pressure.
Proprietary IDOSE PlatformThe integrated IDOSE platform represents a structural competitive asset: combining spectroscopy, dosimetry and planning creates a differentiated product moat. This technical integration supports reproducible clinical protocols and can improve adoption by providers over a multi-month commercialization and regulatory pathway.
Focused Initial Clinical IndicationA concentrated go-to-market on recurrent prostate cancer gives a clear regulatory, clinical and commercialization roadmap. Narrow indication focus can accelerate evidence generation, streamline trials and target key opinion leaders, improving odds of near-term clinical adoption and reimbursement progress.
Bears Say
Negligible Revenue And Widening LossesPersistently negligible revenue alongside sharply larger net losses shows the business has yet to reach commercial scale. Continued wide losses over multiple periods increase reliance on external funding and raise execution risk for product commercialization in the 2–6 month horizon.
Sustained Negative Operating And Free Cash FlowMaterial and persistent negative operating and free cash flow indicate ongoing cash burn that will deplete resources without financing or rapid revenue pickup. This undermines runway, forces potential dilution, and constrains investment in commercialization or regulatory activities over coming months.
Declining Equity And Negative ROEFalling equity and a deeply negative ROE reflect value erosion from repeated losses. Over a medium horizon this heightens financing vulnerability and dilutive risk: without meaningful revenue or margin improvement, shareholder value is likely to be further diluted by any required capital raises.
SPEC FAQ
What was SpectraCure AB’s price range in the past 12 months?
SpectraCure AB lowest stock price was kr0.03 and its highest was kr0.24 in the past 12 months.
What is SpectraCure AB’s market cap?
SpectraCure AB’s market cap is kr56.83M.
When is SpectraCure AB’s upcoming earnings report date?
SpectraCure AB’s upcoming earnings report date is Aug 21, 2026 which is in 18 days.
How were SpectraCure AB’s earnings last quarter?
SpectraCure AB released its earnings results on May 27, 2026. The company reported -kr0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.009.
Is SpectraCure AB overvalued?
According to Wall Street analysts SpectraCure AB’s price is currently Overvalued.
Does SpectraCure AB pay dividends?
SpectraCure AB does not currently pay dividends.
What is SpectraCure AB’s EPS estimate?
SpectraCure AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SpectraCure AB have?
SpectraCure AB has 1,711,808,500 shares outstanding.
What happened to SpectraCure AB’s price movement after its last earnings report?
SpectraCure AB reported an EPS of -kr0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 14.085%.
Which hedge fund is a major shareholder of SpectraCure AB?
Currently, no hedge funds are holding shares in SE:SPEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SpectraCure AB
SpectraCure AB (publ) specializes in oncology, developing innovative cancer treatments that harness laser light and photodynamic agents. A cornerstone of their research is the IDOSE software, which powers an interstitial photodynamic therapy (PDT) system. This cutting-edge system is currently in Phase II clinical trials, where its efficacy in addressing solid tumors is being evaluated. The Swedish company, established in Lund in 2003, continues to advance its therapeutic solutions.